Jeff Johnson
Stock Analyst at Baird
(4.69)
# 137
Out of 4,784 analysts
143
Total ratings
60%
Success rate
31.39%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Outperform | $117 → $107 | $83.85 | +27.61% | 16 | Mar 7, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $37 → $33 | $19.04 | +73.32% | 15 | Feb 27, 2025 | |
| ALC Alcon | Maintains: Outperform | $104 → $108 | $96.10 | +12.39% | 9 | Feb 27, 2025 | |
| BBNX Beta Bionics | Initiates: Neutral | $20 | $11.84 | +68.92% | 1 | Feb 20, 2025 | |
| DXCM DexCom | Upgrades: Outperform | $86 → $104 | $68.42 | +52.00% | 13 | Jan 16, 2025 | |
| PDCO Patterson Companies | Maintains: Neutral | $25 → $31 | $31.27 | -0.86% | 7 | Dec 12, 2024 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $22 | $17.16 | +28.24% | 7 | Oct 31, 2024 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $364.82 | +11.01% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $159.07 | +73.51% | 18 | Oct 24, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $155 → $145 | $112.57 | +28.81% | 13 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $92 → $82 | $69.05 | +18.75% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $258.47 | -7.92% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $37.71 | +85.63% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $17.77 | +243.28% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $15.08 | +344.44% | 6 | Feb 18, 2022 |
The Cooper Companies
Mar 7, 2025
Maintains: Outperform
Price Target: $117 → $107
Current: $83.85
Upside: +27.61%
Tandem Diabetes Care
Feb 27, 2025
Maintains: Neutral
Price Target: $37 → $33
Current: $19.04
Upside: +73.32%
Alcon
Feb 27, 2025
Maintains: Outperform
Price Target: $104 → $108
Current: $96.10
Upside: +12.39%
Beta Bionics
Feb 20, 2025
Initiates: Neutral
Price Target: $20
Current: $11.84
Upside: +68.92%
DexCom
Jan 16, 2025
Upgrades: Outperform
Price Target: $86 → $104
Current: $68.42
Upside: +52.00%
Patterson Companies
Dec 12, 2024
Maintains: Neutral
Price Target: $25 → $31
Current: $31.27
Upside: -0.86%
Envista Holdings
Oct 31, 2024
Maintains: Neutral
Price Target: $17 → $22
Current: $17.16
Upside: +28.24%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $364.82
Upside: +11.01%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $159.07
Upside: +73.51%
Zimmer Biomet Holdings
Aug 8, 2024
Maintains: Outperform
Price Target: $155 → $145
Current: $112.57
Upside: +28.81%
Aug 7, 2024
Maintains: Outperform
Price Target: $92 → $82
Current: $69.05
Upside: +18.75%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $258.47
Upside: -7.92%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $37.71
Upside: +85.63%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $17.77
Upside: +243.28%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $15.08
Upside: +344.44%